CAR T-Cell Therapy
Home >  Cancer (Oncology) >  Services and Treatments >  Immunotherapy >  CAR T-Cell Therapy
Print

Services and Treatments

CAR T-Cell Therapy

Montefiore Einstein Center for Cancer Care offers patients access to an innovative form of cancer treatment for leukemia and refractory and a possible cure for aggressive non-Hodgkin's lymphoma that has not responded to other therapies, including a bone marrow transplant.

Chimeric antigen receptor cell therapy (also called CAR T-cell therapy) is an emerging immunotherapy that involves removing blood cancer patients' T-cells and engineering them to target the cancer before they are given back into the patient. In the immune system, T-cells track down and destroy abnormal cells—including cancer cells.

CAR T-cell therapy provides a viable option for some patients when traditional therapies fail. Data shows at least 50 percent of patients with lymphoma and more than 80 percent of patients with leukemia go into a complete remission after this therapy. Follow-up care is lifelong and consists of regular doctor visits.

Montefiore is one of only three medical centers in the New York metropolitan area that is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) for the full spectrum of adult and pediatric stem cell transplant procedures.

What to Expect During CAR T-Cell Therapy

Candidates for CAR T-cell therapy undergo a procedure to collect white blood cells (lymphocytes) that are part of the body's immune system. Lymphocytes produce antibodies that are able to attack invading bacteria, viruses and toxins. There are two main types of lymphocytes: B-cells and T-cells. T-cells destroy the body's own cells that have been taken over by viruses or have become cancerous.

Lymphocytes are then sent to the laboratory, where the T-cells are separated and genetically modified, using a disarmed virus that can produce receptors called CARS on the cell surface. This process of modification creates an individualized treatment that will target specific markers on a patient's cancer.

After light chemotherapy, the genetically-modified lymphocytes are then infused into the patient's cells, followed by inpatient care and monitoring. Follow-up care includes testing and monthly checkups. Go here to learn more about what to expect during CAR T-Cell therapy.

Have questions? Call 718-920-4826 or email us for additional information on CAR T-cell therapy at Montefiore.